Amneal Pharmaceuticals (AMRX) Tops Q1 EPS by 11c, Offers FY Guidance

Amneal Pharmaceuticals (: AMRX) reported Q1 EPS of $0.20, $0.11 better than the analyst estimate of $0.09. Revenue for the quarter came in at $499 million versus the consensus estimate of $444.23 million.

GUIDANCE:

Amneal Pharmaceuticals sees FY2020 EPS of $0.45-$0.60, versus the consensus of $0.49. Amneal Pharmaceuticals sees FY2020 revenue of $1.875-1.975 billion, versus the consensus of $1.87 billion.

For earnings history and earnings-related data on Amneal Pharmaceuticals (AMRX) click here.

You May Also Be Interested In

• Oracle (ORCL) Tops Q1 EPS by 19c, Beats on Revenue; Beats on Cloud Revenue, Offers Q3 EPS Guidance
• Shoe Station Group Inc. (SHOE) Tops Q2 EPS by 11c ; Offers Guidance
• Oracle raises full year profit guidance, stock rises after hours